GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Laekna Inc (HKSE:02105) » Definitions » Net Current Asset Value

Laekna (HKSE:02105) Net Current Asset Value : HK$1.85 (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Laekna Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Laekna's net current asset value per share for the quarter that ended in Dec. 2023 was HK$1.85.

The historical rank and industry rank for Laekna's Net Current Asset Value or its related term are showing as below:

HKSE:02105' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.68   Med: 10.76   Max: 10.76
Current: 3.78

During the past 3 years, the highest Price-to-Net-Current-Asset-Value Ratio of Laekna was 10.76. The lowest was 3.68. And the median was 10.76.

HKSE:02105's Price-to-Net-Current-Asset-Value is ranked better than
52.58% of 1027 companies
in the Biotechnology industry
Industry Median: 4.01 vs HKSE:02105: 3.78

Laekna Net Current Asset Value Historical Data

The historical data trend for Laekna's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Laekna Net Current Asset Value Chart

Laekna Annual Data
Trend Dec21 Dec22 Dec23
Net Current Asset Value
-3.96 -5.87 1.85

Laekna Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
Net Current Asset Value -3.96 - -5.87 2.29 1.85

Competitive Comparison of Laekna's Net Current Asset Value

For the Biotechnology subindustry, Laekna's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Laekna's Price-to-Net-Current-Asset-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Laekna's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Laekna's Price-to-Net-Current-Asset-Value falls into.



Laekna Net Current Asset Value Calculation

Laekna's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2023 is calculated as

Net Current Asset Value Per Share(A: Dec. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(861.951-140.366-0-0)/390.1
=1.85

Laekna's Net Current Asset Value (NCAV) per share for the quarter that ended in Dec. 2023 is calculated as

Net Current Asset Value Per Share(Q: Dec. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(861.951-140.366-0-0)/390.1
=1.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Laekna  (HKSE:02105) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


Laekna Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of Laekna's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Laekna (HKSE:02105) Business Description

Traded in Other Exchanges
N/A
Address
No. 987, Cailun Road, 5th Floor, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, CHN, 201203
Laekna Inc is a science-driven, clinical-stage biotechnology company. The company has established a comprehensive R&D infrastructure to accelerate the development of molecules from discovery to registrational trials. It has initiated one clinical trial and another five clinical trials for its Core Products LAE002 and LAE001. Among these six clinical trials, three multi-regional clinical trials (MRCTs) are designed to address medical needs in the standard of care (SOC)-resistant cancers. Laekna has two Core Products and 14 other pipeline product candidates. Core Product LAE002 is an adenosine triphosphate (ATP) competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer and PD-1/PD-L1 drug-resistant solid tumors.
Executives
Gp Healthcare Capital, Inc. 2101 Beneficial owner
Shang Hai Jin Pu Yi Liao Jian Kang Gu Quan Tou Zi Ji Jin Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Shang Hai Jin Pu Yi Liao Jian Kang Gu Quan Tou Zi He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Liu Zeng 2201 Interest of corporation controlled by you
Zhong Yi Ning Bo Sheng Tai Yuan Kong Gu Ji Tuan You Xian Gong Si 2201 Interest of corporation controlled by you
Ning Bo Yao Shang Yan Chuang Si Mu Ji Jin Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Ning Bo Yao Shang Yan Chuang Shou Ren Gu Quan Tou Zi You Xian Gong Si 2201 Interest of corporation controlled by you
Ning Bo Yan Chuang Hou De Tou Zi Ji Tuan You Xian Gong Si 2201 Interest of corporation controlled by you
Bei Jing Chun Lin Xin Xi Zi Xun Zhong Xin You Xian He Huo 2201 Interest of corporation controlled by you
Bei Jing An Long Chuang Ye Tou Zi Ji Jin You Xian He Huo 2201 Interest of corporation controlled by you
Liu Ying 2201 Interest of corporation controlled by you
Guo Tou Zhao Shang Tou Zi Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Xian Jin Zhi Zao Chan Ye Tou Zi Ji Jin Er Qi You Xian He Huo 2101 Beneficial owner
Yu Yao Yang Ming Gu Quan Tou Zi Ji Jin You Xian Gong Si 2101 Beneficial owner
Futu Trustee Limited 2301 Trustee

Laekna (HKSE:02105) Headlines

No Headlines